On January 8th, OpenAI introduced ChatGPT for Healthcare, a generative AI (GAI) platform designed to be embedded within medical systems platforms and daily workflows. This technology suite is advertised as a solution to clinicians overburdened by administrative work through offloading cognitively taxing tasks, including the choice of diagnostic tests, supporting differential diagnosis, treatment planning, documenting session notes, creating aftercare plans for patients, and generating referral notes and discharge summaries for external providers. In other words, GAI is being implemented at every level of patient care. According to the American Medical Association’s report from their summit on AI, “disruption” of the status quo in healthcare delivery due to GAI technologies “seems inevitable.”
But why does it seem inevitable? An evidenced-based approach to evaluating new technologies would call for careful consideration of benefits and risks for technology implementation on individual use cases — not a rapid systems overhaul. Here, we must recognize that GAI technologies are products — and these products are being actively promoted to healthcare industries and healthcare professionals across the medical space, including in mental health care. Rather than investing billions of dollars into curtailing a failing system of private medical care — which has led to widespread clinician burnout and poor client outcomes — Silicon Valley companies have begun attempting to mud over these fault lines with a quick-drying GAI compound. Even the most well-meaning and justice-oriented clinician is not immune to the tidal wave of billion-dollar marketing strategies bent on creating the illusion of inevitability.